IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures

IM Therapeutics was founded by world-class physician scientists at the Barbara Davis Center for Diabetes, University of Colorado. Their seminal research showed that blocking action of certain human leukocyte antigen (HLA) gene variants known to be high risk factors blocks the corresponding autoimmune response. As the first such personalized therapy approach in autoimmunity, the Company demonstrated this in a Phase 1b human study in patients recently diagnosed type 1 diabetes who were positive for the HLA DQ8 variant. The study was funded in part by JDRF. The Company is advancing its lead oral drug, IMT-002, through IND development for type 1 diabetes and expanding its core therapeutic platform of HLA blockade to other targets of autoimmune disorders including celiac disease.

“Our value has been clear since day one – getting to the root cause of autoimmunity with a targeted therapy approach and making an impact on diseases such as type 1 diabetes,” said Nandan Padukone, Ph.D., CEO of IM Therapeutics. “We believe the expertise brought by the JDRF T1D Fund and Morningside Ventures will help us build a broad portfolio in autoimmune disease.” Dr. Padukone worked with the T1D Fund team as an Entrepreneur-in-Residence and with IM Therapeutics founders, Drs. Peter Gottlieb and Aaron Michels, to launch the Company’s platform and advance its clinical pipeline.

“We are excited to be a lead investor in IM Therapeutics and are encouraged by the early results of their lead drug in T1D,” said Katie Ellias, Managing Director, at the JDRF T1D Fund. “We believe the company’s platform could be a game-changer not only for T1D but also for other autoimmune diseases.”

IM Therapeutics’ innovative therapeutic approach is currently directed at HLA-DQ8 and DQ2 variants known to predispose individuals to both T1D and Celiac disease. HLA-DQ8 is present in about 60% of T1D patients and in 10% of Celiac disease, while nearly 100% of Celiac patients have DQ2 and/or DQ8 with DQ2 present in about 90% of Celiac disease. The Company has been the first to demonstrate in a clinical study that treating patients based on HLA DQ8 can inhibit the autoimmune response in T1D. With a robust technology platform in place that combines computational chemistry, bioassays, and rational drug design, IM Therapeutics is developing a pipeline against HLA targets in various autoimmune diseases.

Sean Doherty, Executive Chairman, JDRF T1D Fund and Dr. Jason Dinges, Investment Advisor, Morningside Ventures, have joined the IM Therapeutics Board of Directors.

About IM Therapeutics

IM Therapeutics is developing personalized medicines for autoimmune diseases by building oral drug therapies against human leukocyte antigen (HLA) variants that confer high risk of disease. The Company platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates. Its lead drug, IMT-002, is directed at HLA DQ8 activity for treatment of type 1 diabetes. The Company is building a broad pipeline of drugs against HLA targets in autoimmune disorders including celiac disease. http://imtherapeutics.com/

JDRF T1D Fund

The JDRF T1D Fund (https://t1dfund.org/) is a venture philanthropy fund accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Morningside Ventures

Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility. For more information, visit http://www.morningside.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005115/en/